Principal Financial Group
GLUE icon

Principal Financial Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Principal Financial Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$697K Buy
+42,391
New +$811K ﹤0.01% 1994
2023
Q2 		– Sell
-11,395
Closed -$88.8K – 2449
2023
Q1 		$88.8K Buy
11,395
+1,021
+10% +$7.1K ﹤0.01% 2312
2022
Q4 		$78.9K Buy
+10,374
New +$86.4K ﹤0.01% 2330

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Principal Financial Group's GLUE Position: Q1 2026 in Review

Principal Financial Group opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 42,391 shares worth $697K. The stake represents ﹤0.01% of the portfolio and ranks #1994 among its holdings. This is a return to the name: Principal Financial Group previously reported a position in GLUE as recently as Q1 2023.

Principal Financial Group first reported a position in GLUE in Q4 2022 and has held it in 3 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Principal Financial Group held 42,391 shares of Monte Rosa Therapeutics worth $697K as of Q1 2026.
  • Monte Rosa Therapeutics was a new Principal Financial Group position in Q1 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q1 2026, its #1994 holding.
  • Principal Financial Group first reported a position in Monte Rosa Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.